Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Synaptogenix Inc (SNPX)

Synaptogenix Inc (SNPX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 4,732
  • Shares Outstanding, K 1,085
  • Annual Sales, $ 0 K
  • Annual Income, $ -6,040 K
  • 60-Month Beta 1.33
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.18
Trade SNPX with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr N/A
See More
  • Average Estimate N/A
  • Number of Estimates N/A
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year N/A
  • Growth Rate Est. (year over year) N/A

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.86 +18.76%
on 04/03/24
6.22 -26.17%
on 04/08/24
-0.09 (-1.87%)
since 03/22/24
3-Month
3.53 +30.12%
on 02/13/24
7.22 -36.45%
on 02/21/24
-0.28 (-5.85%)
since 01/23/24
52-Week
3.53 +30.12%
on 02/13/24
47.00 -90.23%
on 07/13/23
-19.66 (-81.07%)
since 04/21/23

Most Recent Stories

More News
Bryostatin-1 from Synaptogenix Shows Statistically Significant Results as an ALS Treatment in Pre-Clinical Independent Study

/PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX) ("Synaptogenix" or the "Company"), an emerging biopharmaceutical company developing therapeutics for...

SNPX : 4.61 (+5.68%)
Synaptogenix and Cleveland Clinic to Submit Investigational New Drug (IND) Application to FDA for Clinical Trial of Bryostatin-1 in Multiple Sclerosis

/PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX) ("Synaptogenix" or the "Company"), an emerging biopharmaceutical company developing regenerative therapeutics...

SNPX : 4.61 (+5.68%)
Synaptogenix Provides Corporate Update and Outlines Potential Business Opportunities

/PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX) ("Synaptogenix" or the "Company"), an emerging biopharmaceutical company developing regenerative therapeutics...

SNPX : 4.61 (+5.68%)
Pre-Market Brief: Stocks Mixed As Recession, Rate Hike Fears Persist

March S&P 500 futures (ESH23) are trending up +0.39% this morning after three major U.S. benchmark indices slid for a third successive session and suffered a second consecutive week of losses on Friday...

ESH23 : 3,957.05s (-0.09%)
ARDX : 6.38 (-2.00%)
TSLA : 144.64 (+1.82%)
CTLT : 56.00 (-0.09%)
HEXO : 0.7100 (+2.45%)
SNPX : 4.61 (+5.68%)
Synaptogenix Announces Topline Results from NIH-Sponsored Phase 2 Clinical Trial of Bryostatin-1 for Advanced Alzheimer's Disease

/PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX) ("Synaptogenix" or the "Company"), an emerging biopharmaceutical company developing regenerative therapeutics...

SNPX : 4.61 (+5.68%)
Synaptogenix Welcomes Lecanemab Phase 3 Trial Results

/PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX) ("Synaptogenix" or the "Company"), an emerging biopharmaceutical company developing regenerative therapeutics...

SNPX : 4.61 (+5.68%)
Synaptogenix Announces Live Appearance of its President and CSO on Streaming Financial News Network

/PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX) ("the Company"), a clinical-stage biopharmaceutical company developing regenerative therapeutics for...

SNPX : 4.61 (+5.68%)
Synaptogenix Announces Changes to Scientific Advisory Board in Preparation for Phase 2 Data

/PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX) ("the Company"), a clinical-stage biopharmaceutical company developing regenerative therapeutics for...

SNPX : 4.61 (+5.68%)
Synaptogenix Announces Corporate Update Conference Call

/PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX) ("the Company"), a clinical-stage biopharmaceutical company developing regenerative therapeutics for...

SNPX : 4.61 (+5.68%)
Synaptogenix Advances Dosing of First Patient in Dose Optimization Clinical Trial in Preparation for NIH-Sponsored, Phase 2 Alzheimer's Disease Trial Data

/PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX) ("Synaptogenix" or the "Company"), an emerging biopharmaceutical company developing regenerative therapeutics...

SNPX : 4.61 (+5.68%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 96% Sell with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Synaptogenix Inc. is an emerging biopharmaceutical company. It focused on developing therapies for neurodegenerative diseases. The company's lead therapeutic candidate consist Bryostatin-1. Synaptogenix Inc. is based in NEW YORK.

See More

Key Turning Points

3rd Resistance Point 4.81
2nd Resistance Point 4.65
1st Resistance Point 4.51
Last Price 4.61
1st Support Level 4.21
2nd Support Level 4.05
3rd Support Level 3.91

See More

52-Week High 47.00
Fibonacci 61.8% 30.39
Fibonacci 50% 25.26
Fibonacci 38.2% 20.13
Last Price 4.61
52-Week Low 3.53

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar